ATE83669T1 - Kovalent gebundene komplexe fuer verstaerkte zytotoxizitaet und bildformung. - Google Patents

Kovalent gebundene komplexe fuer verstaerkte zytotoxizitaet und bildformung.

Info

Publication number
ATE83669T1
ATE83669T1 AT89250014T AT89250014T ATE83669T1 AT E83669 T1 ATE83669 T1 AT E83669T1 AT 89250014 T AT89250014 T AT 89250014T AT 89250014 T AT89250014 T AT 89250014T AT E83669 T1 ATE83669 T1 AT E83669T1
Authority
AT
Austria
Prior art keywords
image formation
covalently bonded
enhanced cytotoxicity
bonded complexes
enhanced
Prior art date
Application number
AT89250014T
Other languages
English (en)
Inventor
David C Anderson
A Charles Morgan
Paul G Abrams
Everett J Nichols
Alan R Fritzberg
Original Assignee
Neorx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neorx Corp filed Critical Neorx Corp
Application granted granted Critical
Publication of ATE83669T1 publication Critical patent/ATE83669T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT89250014T 1988-08-15 1989-08-14 Kovalent gebundene komplexe fuer verstaerkte zytotoxizitaet und bildformung. ATE83669T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/232,337 US5135736A (en) 1988-08-15 1988-08-15 Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
EP89250014A EP0359347B1 (de) 1988-08-15 1989-08-14 Kovalent gebundene Komplexe für verstärkte Zytotoxizität und Bildformung

Publications (1)

Publication Number Publication Date
ATE83669T1 true ATE83669T1 (de) 1993-01-15

Family

ID=22872711

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89250014T ATE83669T1 (de) 1988-08-15 1989-08-14 Kovalent gebundene komplexe fuer verstaerkte zytotoxizitaet und bildformung.

Country Status (6)

Country Link
US (1) US5135736A (de)
EP (1) EP0359347B1 (de)
JP (1) JPH02124833A (de)
AT (1) ATE83669T1 (de)
CA (1) CA1334513C (de)
DE (1) DE68904019T2 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
AU2609488A (en) * 1987-11-07 1989-06-01 Agricultural And Food Research Council, The Emulsifiers
US5420105A (en) * 1988-09-23 1995-05-30 Gustavson; Linda M. Polymeric carriers for non-covalent drug conjugation
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
IL93982A0 (en) * 1989-04-03 1991-01-31 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
CA2071969A1 (en) * 1989-12-22 1991-06-23 John R. Murphy Hybrid molecules having translocation region and cell-binding region
GR900100249A (el) * 1990-03-28 1992-06-30 Purdue Research Foundation Μεθοδος δια την ηυξημενην δια των μεμβρανων μεταφοραν εξωγενων μοριων.
US5646120A (en) * 1990-10-24 1997-07-08 Allelix Biopharmaceuticals, Inc. Peptide-based inhibitors of HIV replication
DE4106101A1 (de) * 1991-02-27 1992-09-03 Bayer Ag Fucose-markierte cytostatika
US5328984A (en) * 1991-03-04 1994-07-12 The United States As Represented By The Department Of Health & Human Services Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
US5401489A (en) * 1991-05-01 1995-03-28 University Of New Mexico Biomodulators as universal imaging agents
GB9116925D0 (en) * 1991-08-06 1991-09-18 Antisoma Ltd Novel reagent for tumour imaging and therapy
US5264220A (en) * 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
JPH07501332A (ja) * 1991-11-14 1995-02-09 バッテル・メモリアル・インスティチュート 癌を診断および治療する方法
US5738838A (en) * 1992-02-20 1998-04-14 Rhomed Incorporated IKVAV peptide radiopharmaceutical applications
ATE197767T1 (de) * 1992-01-03 2000-12-15 Rhomed Inc Pharmazeutische anwendungen auf der basis von peptid-metall-ionen
US5556609A (en) * 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
JPH07102147B2 (ja) * 1992-03-16 1995-11-08 株式会社ミドリ十字 ヒト血清アルブミンの着色抑制方法
DE69231123T2 (de) * 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
US5393737A (en) * 1992-08-20 1995-02-28 Health Research, Inc. Cytotoxic drug conjugates for treatment of neoplastic diseases
AU6171894A (en) * 1993-02-12 1994-08-29 Sealite Sciences, Inc. Preparation of photoprotein conjugates and methods of use thereof
US5648218A (en) * 1993-02-12 1997-07-15 Sealite Sciences, Inc. Preparation of photoprotein conjugates and methods of use thereof
WO1994023751A1 (de) * 1993-04-14 1994-10-27 Boehringer Mannheim Gmbh Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
IL106887A (en) * 1993-09-02 1997-02-18 Yissum Res Dev Co Pharmaceutical and diagnostic compositions and a method for drug targeting
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US5716594A (en) * 1994-06-06 1998-02-10 The Jmde Trust Biotin compounds for targetting tumors and sites of infection
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
CA2198361A1 (en) * 1994-09-13 1996-03-21 Ramesh K. Prakash Intracellular delivery of chemical agents to a specific cell type
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
WO1996039183A1 (en) * 1995-05-31 1996-12-12 Fred Hutchinson Cancer Research Center Compositions and methods for targeted delivery of effector molecules
US20030069173A1 (en) 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
EP0832269A1 (de) * 1995-06-07 1998-04-01 Baylor College Of Medicine Nukleinsäure transporter zur abgabe von nukleinsäure in zellen
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
AU5979296A (en) * 1995-06-07 1996-12-30 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
DE19636889A1 (de) * 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
EP1878438B1 (de) * 1997-03-27 2017-11-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand-/lytische peptidzusammensetzungen und verwendungsverfahren
AU6587998A (en) * 1997-03-27 1998-10-20 Demeter Biotechnologies, Ltd. Ligand/lytic peptide compositions and methods of use
JP3794517B2 (ja) * 1997-05-08 2006-07-05 日本メジフィジックス株式会社 腫瘍診断剤
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US6680058B1 (en) 1997-09-03 2004-01-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for contraception in or sterilization of mammals
AU757554B2 (en) * 1998-02-11 2003-02-27 Bracco International B.V. Angiogenesis targeting molecules
KR100722578B1 (ko) 1998-02-23 2007-05-28 아크 테라퓨틱스 리미티드 비오틴-결합 수용체 분자
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
EA200001007A1 (ru) 1998-03-31 2001-04-23 Дюпон Фармасьютикалз Компани Фармацевтические препараты для визуализации ангиогенных расстройств
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US20060263382A1 (en) * 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
US8038984B2 (en) * 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
US7306784B2 (en) 1998-06-20 2007-12-11 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6589503B1 (en) * 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
AU755564B2 (en) * 1998-06-20 2002-12-12 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
DE69904831T2 (de) 1998-07-13 2003-11-06 Univ Texas Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
WO2000027795A1 (en) 1998-11-12 2000-05-18 Invitrogen Corporation Transfection reagents
US7148324B1 (en) * 1998-12-14 2006-12-12 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2349333A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6511648B2 (en) 1998-12-18 2003-01-28 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2001014570A1 (en) 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
WO2001045746A2 (en) * 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
AU2001238501A1 (en) * 2000-02-16 2001-08-27 Bechtel Bwxt Idaho, Llc Selective destruction of cells infected with human immunodeficiency virus
SK12872002A3 (sk) 2000-03-15 2003-05-02 Bristol-Myers Squibb Pharma Company Cielené antineoplastické lieky a ich terapeutické použitie
US7309581B2 (en) * 2000-11-01 2007-12-18 Sysmex Corporation Method of staining, detection and counting bacteria, and a diluent for bacterial stain
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
EP1273308A1 (de) * 2001-07-03 2003-01-08 Fuji Photo Film B.V. Peptid-Flavonoid-Konjugate, ihre Herstellung und Verwendung zum Schutz vor Uv-Strahlung
JP2004535202A (ja) * 2001-07-17 2004-11-25 リサーチ　ディベロップメント　ファンデーション アポトーシス促進性蛋白質を含む治療剤
GB0120022D0 (en) 2001-08-16 2001-10-10 Photobiotics Ltd Conjugate
AU2002332637A1 (en) * 2001-08-22 2003-03-10 Watson Pharmaceuticals, Inc. Conjugates targeted to target receptors
EP1572170A4 (de) * 2002-06-12 2007-02-28 Res Dev Foundation Immunotoxin als therapeutisches mittel und seine verwendungen
US20040126885A1 (en) * 2002-11-05 2004-07-01 Cines Douglas B. Delivery vehicle for recombinant proteins
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US7611692B2 (en) * 2003-01-13 2009-11-03 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7850947B2 (en) 2003-01-13 2010-12-14 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
AU2005228410A1 (en) 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
WO2006073446A2 (en) * 2004-04-28 2006-07-13 The Trustees Of The University Of Pennsylvania Peptide-mediated protein transduction into cells the hematopoietic lineage
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
EP1864134A4 (de) * 2005-02-07 2010-10-20 Univ Columbia Verfahren zur behandlung oder vorbeugung von hormonresistentem prostatakrebs unter verwendung von für protocadherin-pc spezifischer sirna oder anderer inhibitoren der protocadherin-pc-expression oder -aktivität
EP1942944A2 (de) * 2005-10-31 2008-07-16 Genentech, Inc. Makrozyklische depsipeptid-antikörper-wirkstoff-konjugate und entsprechende verfahren
EP2038299A2 (de) 2006-07-11 2009-03-25 Allergan, Inc. Modifizierte clostridientoxine mit verbesserten translokationsfähigkeiten und geänderter targeting-aktivität für nichtclostridientoxin-targetzellen
EP2090322A1 (de) 2008-02-18 2009-08-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung von FSH-Rezeptorliganden zur Diagnose und Behandlung von Krebs
PL219335B1 (pl) * 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
CN101926980B (zh) * 2009-07-29 2012-05-23 中山大学 蛇毒来源的细胞毒素-ctx1在制备戒毒药物中的应用
JP2011116736A (ja) * 2009-10-26 2011-06-16 Otsuka Chem Co Ltd 陽電子放出断層撮影法に用いられるトレーサー及びその製造方法
CN103030687B (zh) * 2013-01-10 2014-02-12 中国人民解放军第二军医大学 青环海蛇抗炎活性肽Hydrostatin-SN1及其编码基因和在制药中的应用
WO2015191764A1 (en) 2014-06-11 2015-12-17 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
US20160347798A1 (en) 2014-01-27 2016-12-01 Molecular Templates, Inc. Mhc class i epitope delivering polypeptides and cell-targeted molecules for direct cell killing and immune stimulation via mhc class i presentation and methods regarding the same
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
AU2016215205B2 (en) 2015-02-05 2021-10-21 Molecular Templates, Inc. Multivalent CD20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
EP3660035A1 (de) 2015-05-30 2020-06-03 Molecular Templates, Inc. Deimmunisierte shigatoxin-a-untereinheitsgerüste und zellgerichtete moleküle damit
CN110494443A (zh) 2016-12-07 2019-11-22 分子模板公司 用于位点特异性缀合的志贺毒素a亚基效应子多肽、志贺毒素效应子支架和细胞靶向分子
US20200024312A1 (en) 2017-01-25 2020-01-23 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
MX2019009726A (es) 2018-04-17 2020-02-05 Molecular Templates Inc Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.
CN112533640A (zh) * 2018-05-04 2021-03-19 双亥生命科学株式会社 利用基于蜂毒肽的细胞凋亡诱导肽的m2型肿瘤相关巨噬细胞的靶向

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541435A (en) * 1975-02-04 1979-02-28 Searle & Co Immunological materials
DE3369466D1 (en) * 1982-05-12 1987-03-05 Harvard College Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
NO881077L (no) * 1987-03-11 1988-09-12 Univ Michigan Kjemo-radio-immuno-konjugater.
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance

Also Published As

Publication number Publication date
DE68904019T2 (de) 1993-07-01
CA1334513C (en) 1995-02-21
EP0359347A2 (de) 1990-03-21
US5135736A (en) 1992-08-04
EP0359347A3 (en) 1990-04-18
JPH02124833A (ja) 1990-05-14
EP0359347B1 (de) 1992-12-23
DE68904019D1 (de) 1993-02-04

Similar Documents

Publication Publication Date Title
ATE83669T1 (de) Kovalent gebundene komplexe fuer verstaerkte zytotoxizitaet und bildformung.
FI972514A0 (fi) Kasvainspesifisten sytotoksisten T-solujen in vivo aktivointi
AU1375188A (en) Metal-radionuclide-labeled proteins and glycoproteins for diagnosis and therapy
EP0335910A4 (de) Intraoperative erstellung des befundes und tumor-therapie mittels endoskop.
ES2152986T3 (es) Genoterapia de celulas mesoteliales.
IL52119A0 (en) Vehicle substances which are capable of covalent bonding with biologically active matter and their preparation
ES2078521T3 (es) Nuevos conjugados de proteina-polication.
EP0526700A3 (de)
ES2100452T3 (es) Composiciones de liposomas de fotosensibilizadores de porfirina.
EG18751A (en) Antibody - enzime conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
IL88428A0 (en) Anti-tumor drug-monoclonal antibody conjugates
DK382989A (da) Cytotoxiske vinca-konjugater bundet til antistoffer og fremgangsmaade til fremstilling deraf
DE69822496D1 (de) Lipidkomplex-lyophilisat von wasserunlöslichen porphyrinen
FR2763943B1 (fr) Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
DE3780434D1 (de) Hinterachsgehaeuse und dessen herstellung.
ATE82857T1 (de) Interleukin-2-zusammensetzungen.
MX9102086A (es) Complejos que contienen acidos s(+) fenilalcanos y amino-azucares
FI872016A0 (fi) Trikaovaror och foerfarande foer deras framstaellning.
EP0318948A3 (en) Cleavable immunoconjugates for the delivery and release of agents in native form
ZA793234B (en) Indole derivatives and their use as antianxiety drugs or sedatives
ATE187890T1 (de) Ligandgerichtete enzyme-prodrug therapie
PT88539A (pt) Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
ATE99959T1 (de) Immunokonjugate fuer krebs-diagnose und -therapie.
FR2577800B1 (fr) Medicament sous forme galenique gastro-resistante
ES291194U (es) Panal perfeccionado

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties